DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Callahan MK. et al.
Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC).
J Clin Oncol 2017;
35: 384-384 (suppl 6S; abstract 384) DOI: 10.1200/JCO.2017.35.6_suppl.384, no. 6_suppl [February 2017])
Access:
We do not assume any responsibility for the contents of the web pages of other providers.